| Literature DB >> 18366653 |
Kim M Pepin1, Holly A Wichman.
Abstract
BACKGROUND: In large asexual populations where beneficial mutations may co-occur and recombination is absent, the fate of beneficial mutations can be significantly affected by competition (i.e., clonal interference). Theoretical models predict that clonal interference (CI) can slow adaptation, alter the distribution of fixed beneficial mutations, and affect disease progression by impacting within-host evolution of pathogens. While phenotypic data support that CI is a significant determinant of adaptive outcome, genetic data are needed to verify the patterns and to inform evolutionary models. We adapted replicate populations of the bacteriophage phiX174 under two levels of CaCl2 to create benign and harsh environments. Genomic sequences of multiple individuals from evolved populations were used to detect competing beneficial mutations.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18366653 PMCID: PMC2292699 DOI: 10.1186/1471-2148-8-85
Source DB: PubMed Journal: BMC Evol Biol ISSN: 1471-2148 Impact factor: 3.260
Figure 1Adaptation and selection strength. (A) Change in fitness for each experimental line. Data are means for five replicate, paired fitness assays of the ancestor and the endpoint population of each line in its respective treatment. anc: black lines (all line 1), anc788: grey lines, solid grey: line 2, dashed grey: line 3, circles: harsh, triangles: benign. (B) Fitness of each ancestor relative to endpoint populations (n = 5). Data from benign environments are pooled, as are data from lines 2 and 3 for anc788 (within the H and B treatments). Bars are 95% confidence intervals from t-tests of mean differences between the harsh (H) and benign (B) treatments for each ancestor. (C) Mean selection coefficient of mutations in endpoint populations (n = 5). Data from benign environments are pooled, as are data from lines 2 and 3 for anc788 (within the H and B treatments). Bars are 95% confidence intervals from t-tests of mean differences between the harsh (H) and benign (B) treatments for each ancestor. (D) The change in fitness as a proportion of total fitness (n = 5). Data from benign environments are pooled, as are data from lines 2 and 3 for anc788 (within the H and B treatments). Bars are 95% confidence intervals from t-tests of mean differences between the harsh (H) and benign (B) treatments for each ancestor.
Parameters of Experimental Evolutions.
| Per flask: (means) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatments | Line | Total hrs | Total flasks | ||||||||
| Control | 1 | 1.8 × 106 | 5.7 × 109 | 0.0003 | 74.8 | 147 | 16.3 | 20.5 | 4.1 | 1.4 | 0.20 |
| Benign | 1 | 1.6 × 106 | 6.4 × 109 | 0.0003 | 70.8 | 138 | 16.3 | 20.2 | 3.9 | 2.1 | 0.19 |
| Control | 2 | 2.3 × 106 | 3.5 × 109 | 0.0006 | 87.4 | 174 | 18.0 | 19.7 | 1.7 | 0.8 | 0.086 |
| 3 | 1.3 × 106 | 4.8 × 109 | 0.0003 | 63.5 | 126 | 19.1 | 21.2 | 2.2 | 1.1 | 0.10 | |
| Benign | 2 | 3.1 × 106 | 7.9 × 109 | 0.0004 | 38.4 | 76 | 17.9 | 19.8 | 1.9 | 1.9 | 0.097 |
| 3 | 3.2 × 106 | 7.5 × 109 | 0.0004 | 43 | 85 | 18.5 | 20.9 | 2.4 | 1.3 | 0.11 | |
Treatment: Control = 2.0 mM CaCl2, Benign = 1.7 mM CaCl2, Harsh = 0.2 mM CaCl2.
Nand N30: Mean phage population sizes at the start and end of each flask growth period.
N/N30: Bottleneck size; lower numbers indicate lines where beneficial mutations had higher extinction probabilities from bottlenecks.
w: Mean fitness of the ancestor in treatment conditions (n = 5).
w: Mean fitness of the endpoint populations in treatment conditions (n = 5).
relW: Mean fitness of the evolved population relative to ancestor (n = 5).
S: Mean selection coefficient; a measure of selection strength.
relW/w: Fitness change as a proportion of total fitness; a measure of selection strength.
"Harsh" treatments are shown in bold.
Genotypes Identified by Genome Sequencing.
| Anc | Treatment | Line | a | b | a | b | c | d |
|---|---|---|---|---|---|---|---|---|
| anc | Control | 1 | 10/10 | 5/9 | n, Y | 5 | ||
| 2/9 | ||||||||
| 2/9 | ||||||||
| anc | Benign | 1 | 2/10 | 2/10 | Y, Y | 3 | ||
| 2/10 | 3/10 | |||||||
| 878 | 5/10 | 5/10 | ||||||
| 878, | 1/10 | |||||||
| anc | Harsh | 1 | ND | 9/9 | --, n | 1 | ||
| anc788 | Control | 2 | ND | 8/10 | --, y | 3 | ||
| 1/10 | ||||||||
| 1/10 | ||||||||
| anc788 | Control | 3 | none | 1/10 | 1302 | 1/10 | Y, Y | 3 |
| 1302 | 3/10 | 1302, | 6/10 | |||||
| 1/10 | 1302, | 2/10 | ||||||
| 3340 | 4/10 | 1302, 1690 | 1/10 | |||||
| 3340, | 1/10 | |||||||
| anc788 | Benign | 2 | none | 5/9 | 8/10 | y, y | 3 | |
| 2/9 | 1/10 | |||||||
| 1/9 | 1/10 | |||||||
| 624 | 1/9 | |||||||
| anc788 | Benign | 3 | ND | 8/9 | --, n | 2 | ||
| 1/9 | ||||||||
| anc788 | Harsh | 2 | ND | 10/10 | --, n | 2 | ||
| anc788 | Harsh | 3 | none | 2/9 | 3039 | 2/10 | n, n | 2 |
| 3039, 1138 | 1/9 | 3039, | 8/10 | |||||
| 3039 | 6/9 |
a Numbers indicate nucleotide positions that are different from ancestor; rows list the mutational position(s) for a single genotype. ND = not done; Bold = parallel mutations.
b Total number of genotypes over total number of isolates sequenced.
c CI status of mid- and endpoint populations; y means that multiple mutually exclusive genotypes are present (i.e., A versus B, or AB versus AC, but NOT A versus AB; the latter condition is simply a selective sweep in progress, not competition between genotypes). Y = strong CI, where multiple isolates of competing mutations were observed; y = weak CI, where only one competing isolate was observed.
d Number of adaptive mutations in endpoint populations as determined from criteria in Table 3. Data were used for Mann-Whitney U-test of Ho: The number of adaptive mutations sampled in control/benign endpoint populations is similar to the number of adaptive mutations sampled in the harsh populations (i.e., adaptive mutations were not sampled from populations with different distributions of adaptive mutations).
Mutations Identified by Genome Sequencing.
| nt change | |||||||
|---|---|---|---|---|---|---|---|
| 181 | C, B | G | T | C17, K44 | A, C | S, F | Parallel High frequency Previous (3) |
| 563 | C, B | C | T | (D58) | - | - | Parallel High frequency Previous (1) |
| 576 | C | C | T | (E3), (D63) | - | - | High frequency Previous (1) |
| 581 | C | C | T | E5, (D64) | T,- | I,- | Previous (1) |
| 587 | C | G | T | E7, (D66) | W, - | L, - | Parallel High frequency |
| 593 | C, B | C | T | E9, (D68) | T, - | I, - | Parallel High frequency Previous (1) |
| 624 | B | G | T | D79, E19 E74, | A, L | S, F | |
| 788 | C, B | C | T | (D133) | T,- | M,- | Parallel High frequency Measured |
| 878 | B | T | C | J11 | C | N | High frequency |
| 1033 | C | G | T | F10 | M | I | High frequency Previous (1) |
| 1138 | H | C | T | (F45) | - | - | |
| 1216 | C | C | T | (F71) | - | - | |
| 1295 | C, B | A | G | F98 | N | D | Parallel Previous (6) |
| 1302 | C | C | G | F100 | T | S | Parallel Previous (1) |
| 1611 | C, B | A | G | F203 | H | R | Parallel High frequency Previous (4) Measured |
| 1690 | C | C | T | (F229) | - | - | |
| 1702 | C, B | T | C | (F233) | - | - | Parallel Previous (1) |
| 2772 | B | T | C | (G126) | - | - | High frequency |
| 2971 | H | C | T | H14 | A | V | High frequency Previous (6) |
| 2973 | H | G | A | H15 | G | S | High frequency Previous (1) |
| 3039 | H | G | T | H37 | V | L | High frequency |
| 3129 | H | G | T | H67 | A | S | Parallel High frequency |
| 3340 | C | A | G | H137 | G | D | High frequency Previous (4) |
a Genome position of nucleotide mutation.
b C = control; B = benign; H = harsh.
c Gene product (indicated by letter) and amino acid position of mutation.
d Effect of the mutation at the amino acid level (from amino acid/to amino acid). Gene product C is involved in DNA replication, D is the external scaffolding protein, E is the lysis protein, F is the major capsid protein, G is the minor capsid protein, H is the pilot protein, J is the DNA binding protein, and K is of unknown function. Because φX174 has overlapping reading frames, some changes affect more than one protein.
e Evidence that a particular change is adaptive includes: Parallel = occurrence in multiple lines of this study; High frequency = occurrence in multiple isolates in a population in this study, indicating the change was at high frequency in the population and that there was no evidence of hitchhiking; Previous (#) = occurrence in previous evolution experiments (the number of evolution lineages that the mutation was observed) [24,26-29, and unpublished data]; Measured = measurement of fitness effects. None = no independent evidence that the mutation is adaptive. Of the mutations considered to be adaptive by the criteria above, hitchhiking could not be ruled out for 2973 and 581. However, both of these mutations have occurred previously under very similar experimental conditions and there are additional indicators that these mutations are adaptive: 581 affects an amino acid two away from another that is adaptive in this experiment (protein E, site 7 vs E7), and is also two sites away from a site known to have a large effect on lysis regulation (E3 [32]). Mutation 2973 at H15 is adjacent to site H14 which showed strong evidence of being adaptive.
Parentheses indicate synonymous substitutions.
Frequency of Mutations in Four Genomic Regions.
| Mutation site | Protein | Putative function | Control, Benigna | Harsha |
|---|---|---|---|---|
| 181 | C, K (DNA maturation and accessory proteins) | Burst size | 2 | 0 |
| 563, 576, 587, 593, 788 | D, E (Lysis protein and its regulatory region) | Lysis timing | 10 | 0 |
| 1033, 1295, 1302, 1611, 2772 | F, G (Capsid proteins) | Attachment, stability, assembly | 7 | 0 |
| 2971, 2973, 3039, 3129 | H (Pilot protein) | Eclipse rate: DNA ejection into host | 0 | 5 |
a Numbers are the frequency that mutations from a particular functional category were observed in independent evolution lines under the indicated treatments.
Only adaptive mutations (i.e., satisfying criteria in Table 3) from endpoint populations are shown.
Summary of Endpoint Populations Showing Evidence of CI.
| Endpoint populations | Pooledb Ancestors | Fisher Exact |
|---|---|---|
a Pops with CI: Total number of populations in each treatment (harsh versus benign) showing evidence of CI (as determined in Table 2); Pops with no CI: Total number of populations not showing evidence of CI.
b Number of endpoint populations with or without evidence of CI pooled across both ancestors.
c Ho: The frequency of populations showing CI is not higher in benign conditions.
Figure 2Selection coefficients of two mutations from Line 1 control and benign treatments. Zero indicates fitness of the ancestor. Each point is a mean estimated from five paired replicate fitness measures. Bars are standard errors of mean selection coefficients (circle: C788T; triangle: A1611G).